Understanding how the immune system can fight brain tumors in patients with specific genetic mutations.
Official title: Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
Funded at University of Pennsylvania · NIH-10880594 · Data updated 2026-11-12
This study is looking at how the immune system works with a specific type of brain tumor called IDH-mutant gliomas and testing if certain treatments can help boost the body's ability to fight these tumors, with the goal of finding better, personalized treatment options for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 3, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $689,044 |
| NIH project number | 5R37CA284132-02 |
| Project ID | NIH-10880594 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with IDH-mutant gliomas who are seeking new treatment options.
✕Less likely to help
Patients with gliomas that do not have IDH mutations or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how the immune system interacts with IDH-mutant gliomas, a type of brain tumor, and how treatments like All-Trans Retinoic Acid and PD-1 inhibitors can enhance anti-tumor immunity. By analyzing both human clinical trial data and mouse models, the researchers aim to identify immune biomarkers and key immune cell types that can predict how well these tumors respond to therapy. This approach could lead to more effective treatment strategies tailored to individual patients based on their tumor's characteristics.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with IDH-mutant gliomas, potentially increasing survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using immunotherapy for brain tumors, but this specific approach focusing on IDH mutations and combined therapies is relatively novel.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Amankulor, Nduka Mgbechinyere — University of Pennsylvania
- Study coordinator: Amankulor, Nduka Mgbechinyere
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.